Assessing the Socioeconomic Impact of Alzheimer's Disease in Western Europe and Canada

To assess the socioeconomic burden of Alzheimer’s and other dementias as well as the associated challenges facing policymakers, governments and society, The Economist Intelligence Unit has conducted a study of six countries—Canada, France, Germany, Italy, Spain and the UK—to examine the strategies and policies that governments and other key organisations are devising and implementing in their attempts to tackle the socioeconomic impact of these diseases.

Assessing the Socioeconomic Impact of Alzheimer's Disease in western Europe and Canada

Assessing the socioeconomic impact of Alzheimer’s in western Europe and Canada is a report by The Economist Intelligence Unit, sponsored by Eli Lilly, which examines how healthcare systems and governments in western Europe and Canada are responding to the growing pressures that Alzheimer’s disease and other dementias are placing on their economy, society and healthcare systems.

How can research stem the tide of the NCD pandemic?

Governments should consider long-term investments in high-quality peer-reviewed implementation research to tackle the growth of non-communicable diseases (NCDs) in developing countries.

How countries are failing to integrate people with mental illness into society

In opening The Economist's summit on The Global Crisis of Depression in 2014, Kofi Annan, former UN secretary-general, said: "Depression must become a global priority because it not only affects health and well-being but also diminishes labour productivity and economic growth. Calling the challenge of depression a global crisis is no exaggeration at all." The urgency to address this growing societal crisis has not diminished since then. However, research from The Economist Intelligence Unit highlights major deficits in policies to integrate the mentally ill into society.

Developing countries are ill-equipped to manage the growing chronic-disease burden

As World Health Day is celebrated around the globe on April 7th, the rising burden of chronic diseases in developing countries must become a priority for global health policy. Healthcare systems in many developing countries have evolved to cope with the burden of infectious diseases and to improve child and maternal health. There is now a pressing need to include the prevention and management of chronic diseases in these systems, requiring new thinking on how such medical services are financed.

How to quantify investment in health leaders

Now, more than ever, the value of investment needs quantification. How much exactly does X change with Y and for how long? Is it possible to quantify the value of leadership training in health outcomes? How much should be invested in leadership? A core part of health interventions are the professionals that deliver them. These are the people who connect service with patient, with intervention and ultimately with health outcomes. Does building leadership capacity to manage change processes add any value to quality-improvement strategies?

Confronting obesity in Poland, Romania and the Czech Republic

When it comes to confronting the problem of growing rates of obesity, the countries of Central and Eastern Europe (CEE) arguably find themselves in the worst of all possible worlds. While rates of obesity for the Czech Republic, Poland and Romania are generally lower than those for larger EU countries such as Germany and the UK, traditional diets high in sugar and fat as well as sedentary lifestyles have helped to create the ideal “obesogenic” environment.

The three chapters in this report look at the policy response to obesity in Poland, Romania and the Czech Republic. 

Confronting obesity in the Middle East: Cultural, social and policy challenges

Bringing healthcare to hard-hit areas in Bangladesh

Q&A with Runa Khan, founder of Friendship, a Dhaka-based non-governmental organisation that uses clinics on barges to deliver mobile healthcare to people in impoverished and flood-prone areas of Bangladesh.

Heart Health

Cardiovascular diseases (CVDs) remain a leading cause of global mortality. Nearly 18m people die from such diseases each year, according to the World Health Organisation (WHO), accounting for nearly one-third of all deaths worldwide. Many are living with chronic cardiac conditions, such as hypertension, coronary heart disease and heart failure; as populations age and treatments improve, patients are likely to live with their disease for longer periods of time.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week